9,223 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Aquatic Capital Management LLC

Aquatic Capital Management LLC acquired a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 9,223 shares of the company's stock, valued at approximately $516,000.

Other large investors also recently made changes to their positions in the company. Marshall Wace LLP lifted its stake in Rhythm Pharmaceuticals by 70.4% in the fourth quarter. Marshall Wace LLP now owns 692,803 shares of the company's stock valued at $38,783,000 after acquiring an additional 286,188 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Rhythm Pharmaceuticals by 24.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 685,152 shares of the company's stock worth $38,355,000 after purchasing an additional 134,622 shares during the period. Hood River Capital Management LLC increased its position in Rhythm Pharmaceuticals by 4.7% during the fourth quarter. Hood River Capital Management LLC now owns 643,691 shares of the company's stock worth $36,034,000 after buying an additional 29,093 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Rhythm Pharmaceuticals by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 440,250 shares of the company's stock valued at $24,645,000 after buying an additional 6,384 shares during the period. Finally, Pictet Asset Management Holding SA lifted its position in shares of Rhythm Pharmaceuticals by 14.0% in the fourth quarter. Pictet Asset Management Holding SA now owns 375,349 shares of the company's stock valued at $21,012,000 after buying an additional 46,010 shares during the last quarter.

Rhythm Pharmaceuticals Stock Performance

Shares of NASDAQ RYTM traded down $2.23 during mid-day trading on Tuesday, reaching $62.18. The company had a trading volume of 455,539 shares, compared to its average volume of 547,172. Rhythm Pharmaceuticals, Inc. has a one year low of $35.17 and a one year high of $68.58. The business's 50-day simple moving average is $56.31 and its 200 day simple moving average is $56.77. The firm has a market cap of $3.95 billion, a price-to-earnings ratio of -14.34 and a beta of 2.36.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.03). The firm had revenue of $41.83 million during the quarter, compared to analyst estimates of $38.48 million. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. On average, sell-side analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.32 EPS for the current year.

Insider Activity

In other Rhythm Pharmaceuticals news, CAO Christopher Paul German sold 635 shares of the business's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total transaction of $36,334.70. Following the sale, the chief accounting officer now owns 2,070 shares of the company's stock, valued at approximately $118,445.40. The trade was a 23.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer Kayden Lee sold 4,189 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $58.91, for a total transaction of $246,773.99. Following the transaction, the executive vice president now owns 4,409 shares of the company's stock, valued at $259,734.19. This trade represents a 48.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 151,733 shares of company stock worth $8,492,699. Insiders own 5.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on RYTM. Canaccord Genuity Group increased their price target on Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the company a "buy" rating in a research note on Tuesday, April 8th. Bank of America upgraded shares of Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 target price for the company in a research note on Monday, April 7th. Stifel Nicolaus assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Wednesday, March 5th. They issued a "buy" rating and a $78.00 price target on the stock. Needham & Company LLC restated a "buy" rating and set a $66.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Tuesday, April 8th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $72.00 target price on shares of Rhythm Pharmaceuticals in a research report on Friday, March 7th. Thirteen analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $74.92.

Rhythm Pharmaceuticals Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.